HK Stock Market Move | Everest MED-B (01952) rose nearly 5% in early trading. Ophthalmology new drug VIS-101 is planned to start Phase IIb clinical research in the second half of the year.

EVEREST MED-B (01952) rose nearly 5% in the morning session, with a 4.11% increase at the time of publication, reaching 37.96 Hong Kong dollars, with a turnover of 49.5624 million Hong Kong dollars. On the news front, on March 13, EVEREST MED announced that its ongoing ophthalmic pipeline VIS-101 for the treatment of wet age-related macular degeneration (wet AMD) has achieved positive topline data in Phase IIa studies. Based on this positive Phase IIa clinical data, VIS-101 is scheduled to begin Phase IIb clinical trials in the second half of 2026 and initiate global Phase III clinical trials in 2027. It is worth noting that on March 9, EVEREST MED announced that its core product in the field of autoimmune diseases, Velsipity (L-arginine mecobalamin tablets), received its first prescription in mainland China at the First Affiliated Hospital of Sun Yat-sen University, marking the official entry of this innovative therapy into clinical application in China. Velsipity has also simultaneously been prescribed at 8 tertiary hospitals in 7 core cities including Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing and Nanjing, covering key regions nationwide on the first day of its market launch.